Eradication of Helicobacter pylori in 2025 – new recommendations, practical challenges, and effective treatment strategies Artykuł przeglądowy

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Mar 31, 2025
DOI: https://doi.org/10.24292/01.MF.0125.01
Keywords:
Helicobacter pylori, clinical guidelines, eradication therapy, antibiotic resistance, proton pump inhibitors

Main Article Content

Michał Lipiński
1. Klinika Chorób Wewnętrznych, Warszawski Uniwersytet Medyczny; Szpital Grochowski im. dra med. Rafała Masztaka, Warszawa. 2. Centrum Diagnostyki i Leczenia Chorób Trzustki, Centrum Medyczne Med-Gastr, Łódź

Abstract

Helicobacter pylori infection remains a significant clinical challenge, particularly due to the increasing bacterial resistance to antibiotics. This article discusses the latest recommendations for the diagnosis and treatment of H. pylori in 2025, based on both Polish and international guidelines. The indications for testing, diagnostic methods, and current therapeutic regimens are reviewed. The importance of appropriate treatment selection and factors influencing therapeutic success, such as adherence to medical recommendations and proper monitoring of treatment outcomes, is emphasized. A comprehensive approach to diagnosis and treatment, considering individual patient characteristics and epidemiological factors, may improve eradication success rates and reduce the long-term consequences of infection.

Article Details

How to Cite
Lipiński, M. (2025). Eradication of Helicobacter pylori in 2025 – new recommendations, practical challenges, and effective treatment strategies. Medycyna Faktow (J EBM), 18(1(66), 6-9. https://doi.org/10.24292/01.MF.0125.01
Issue
Vol 18 No 1(66) (2025)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Martínez-Domínguez SJ, Nyssen OP, Lanas Á et al. Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg). Helicobacter. 2024; 29(4): e13111.
2. Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P et al. Helicobacter pylori Drug Resistance: Therapy Changes and Challenges. Expert Rev. Gastroenterol. Hepatol. 2018; 12: 819-27.
3. Savitri CMA, Fauzia KA, Alfaray RI et al. Opportunities for Helicobacter pylori Eradication beyond Conventional Antibiotics. Microorganisms. 2024; 12(10): 1986.
4. Bravo D, Hoare A, Soto C et al. Helicobacter pylori in human health and disease: Mechanisms for local gastric and systemic effects. World J Gastroenterol. 2018; 24(28): 3071-89.
5. Bardhan PK. Epidemiological features of Helicobacter pylori infection in developing countries. Clin Infect Dis. 1997; 25(5): 973-8.
6. Li Y, Choi H, Leung K et al Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023; 8(6): 553-64.
7. Jaroń K, Pietrzak A, Daniluk J et al. Diagnostic and therapeutic recommendations on Helicobacter pylori infection. Recommendations of the Working Group of the Polish Society of Gastroenterology. Gastroenterology Rev. 2023; 18: 225-48.
8. Malfertheiner P, Megraud F, Rokkas T et al. European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022: gutjnl-2022-327745.
9. Savoldi A, Carrara E, Graham DY et al. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018; 155(5): 1372-82.e17.
10. Ismail NI, Nawawi KNM, Hsin DCC et al. Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial. Helicobacter. 2023; 28(6): e13017.
11. Zhang Y, Lu B, Dong Y et al. Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradication of Helicobacter pylori infection. Sci Rep. 2024; 14(1): 13152.
12. Shah SC, Bonnet K, Schulte R et al. Helicobacter pylori Management Is Associated with Predominantly Negative Patient Experiences: Results from a Focused Qualitative Analysis. Dig Dis Sci. 2022; 67(9): 4387-94.